# An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

> **NCT05399368** · PHASE2 · TERMINATED · sponsor: **RAPT Therapeutics, Inc.** · enrollment: 229 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** RPT193
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05399368
- **Lead sponsor:** RAPT Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-05-24
- **Target enrollment:** 229 (ACTUAL)
- **Why stopped:** Study on clinical hold by FDA
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399368, "An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05399368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*